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Abstract Psychiatric disorders in migraine patients have a
higher prevalence than general population. The presence of
psychiatric comorbidities may influence the complexity of
the migraine pictures and be related to medication overuse.
Severely impaired chronic migraineurs presenting with
medication overuse are a challenge for headache clinics.
Psychiatric comorbities, such as dependency-like behaviors,
anxiety and mood symptoms, might account for headache-
related disability and recurrent relapses into medication
overuse after a successful detoxification. Within a sample of
63 chronic migraineurs with medication overuse and severe
disability, we investigated to which extent clinical severity,
affective states and attitudes about medication impact the
overall functioning at time of detoxification. To unravel
whether some of these factors could predict their long-term
outcome, we followed and retest them 1 year after with-
drawal. We hypothesized that the detoxification would have
led to a partial improvement and not modified the attitudes
toward medication and dependence. Detoxification improves
most of the clinical and affective measures, but does not free
from significant levels of pain intensity and headache-related
disability. The partial benefit from detoxification, the severity
bias and the maladaptive cognitive profile led us to believe that
subgroups of chronic-relapsing migraineurs deserve a multi-
disciplinary approach that addresses not only the reduction of
clinical severity but also specific cognitive and behavioral
impairments.
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Introduction
Chronic migraine (CM) with Medication overuse (MO) affects
upto 15–30 % of patients with headaches referring to tertiary
care clinics [1–3]. Some of them present dependency-like
behaviors with medications, despite being aware of and con-
cerned about their negative consequences, i.e. compromised
social functioning and severe impact on the quality of life [4,
5]. The underlying neurobiology of MO is not well understood.
Although it might come from coping with pain and disability
associated with migraine, a persistent dysfunction of the
orbitofrontal cortex (OFC) and the relative decision-making
deficit have been recently reported [6–8]. These deficits might
explain the above-mentioned maladaptive behaviors and place
MO in the substance use disorders spectrum [6].
Detoxification from the offending drug is the first line
treatment [9, 10]. However, long-term studies indicate that a
high proportion of patients relapse into MO within months or
years, even after a successful detoxification [11, 12]. Rea-
sons for relapses might go beyond the frequency and the
intensity of headaches.
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First, the comorbidity with anxiety and mood disorders
has been associated with a negative long-term prognosis in
migraine and might play a role in perpetuating MO [13].
A bidirectional influence has been observed between
migraine and depression, with each disorder increasing the
risk for onset of the other [14, 15]. Second, the severity of
dependency-like behaviors and the excessive confidence in
the healing power of medications could jeopardize the
benefit of detoxification and predispose migraneurs to
persist in overusing medications [16–18].
Several studies suggest predictors of relapse after a
successful detoxification in samples of chronic migraineurs
with MO [1, 12, 19–22]. However, in tertiary centers, these
putative factors are present and severe to such an extent
that they could reciprocally influence each other and blur
the clinical presentation and the physician manageability.
The aim of this study was to pick a sample of severely
impaired chronic migraineurs with MO and study whether
some of the predictors described by literature could be
identified as risk factors for relapse. We hypothesized that
detoxification as part of treatments for chronic migraine
with MO would have led only to a partial improvement. To
this purpose, we first delineated how psychopathological
features and attitudes toward medication interact with
clinical features. One year after detoxification, chronic
migraineurs were reevaluated, in order to unravel whether
their long-term outcome could be predicted by their base-
line migraine characteristic, baseline affective states and
their attitudes about medication and dependence.
Methods
Participants
Sixty-three patients with CM and MO were recruited at the
Headache Center of the Foundation IRCCS Neurological
Institute Carlo Besta in Milan, whose Ethics Committee
approved the study.
CM (i.e. migraine headaches present on C15 days in a
month on a regular basis for[3 months) and MO (intake of
simple analgesic on C15 days/month or of any combina-
tion of ergotamine, triptans, analgesics, and/or opioids on
Cdays per month on a regular basis for [3 months) were
diagnosed according to the current criteria of the Interna-
tional Headache Society [23] Exclusion criteria were other
chronic pain conditions, pregnancy, progressive neurolog-
ical disorders, present or past psychotic disorders, present
or past substances and alcohol use disorders, use of anti-
psychotic drugs in the last 6 months. All patients were
informed of the setting-up of the observatory database and
signed a written consent before participating.
After enrollment, patients underwent detoxification in a
5-day Day Hospital regimen and a neuropsychiatric eval-
uation by means of structured and semi-structured instru-
ments. They were encouraged to keep headaches and
medications record and taught how to manage migraine
episodes with NSAIDs and triptans. When needed, after
withdrawal, prophylaxis therapy was prescribed. After
1 year, they underwent the same evaluation in an outpa-
tient regimen, and were classified into two groups: those
who ceased MO and those who relapsed into MO.
Measures
All subjects were evaluated by means of the rating scales
listed below.
The Hamilton Rating Scales for Anxiety and Depression
[24, 25] for the measurement of intensity of depression and
anxiety symptoms. The Migraine Disability Assessment
Questionnaire (MIDAS) [26, 27] which measures head-
ache-related disability in the past 3 months by means of
five questions about work, household and social-related
disability, the frequency of headaches and the intensity of
headache pain (on an 11-point scale, ranging from 0 to 10).
The Severity of Dependence Scale (SDS) [28], originally
created to investigate opiate dependence, used to predict
patterns of MO and dependency-like behaviors among
chronic headache patients [17, 18]. The higher the total
score (range 0–15), the higher the level of dependence. The
Symptom Checklist-90-Revised (SCL-90-R) Self-Report
[29] Last-month is a self-report symptom inventory used in
medical or psychiatric conditions. In the study, we used the
Global Severity Index (GSI) score, which summarizes the
overall psychopathological impairment.
Statistical analysis
All statistical analyses were performed using SPSS 17.0 for
Windows (SPSS Inc, Chicago, IL, USA) and R2.8.1 (R
Development Core Team, 2006). First, correlational anal-
yses were employed to explore possible relations at base-
line between clinical features, affective measures and
attitudes toward medication and dependence. Second, a
series of t test for paired samples was used to assess the
evolution of psychological and clinical features 1 year after
the detoxification. A further series of t test for independent
samples and Chi-squared tests were performed to investi-
gate the differences 1 year after detoxification in all the
studied domains between those who ceased MO and those
who relapsed into it. With the aim of clarifying the value of
single variables in determining the relapse, the disability
and the persistent analgesic intake after detoxification, we
ran a series of bivariate analyses whose outcome variables
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were, respectively, the presence of relapse after 12 months,
the number of tablets per month and the MIDAS total
score. Explanatory variables taken from baseline evalua-
tion were gender, age, years with migraine, years with
medication overuse, frequency of headache per month,
number of tablets per month, intensity of headache pain,
MIDAS total score, past history of psychiatric disorder,
psychiatric diagnosis at time of evaluation, GSI at SCL-
90R questionnaire, scores at Hamilton Rating Scales for
Anxiety and Depression and SDS score.
The normality assumption was assessed using the Kol-
mogorov–Smirnov test, with Lilliefors significance cor-
rection. For bivariate analysis, Kruskal–Wallis rank sum
test and Fisher’s two-tailed exact test were performed to,
respectively, analyze numerical and categorical variables.
Due to the lack of significance in Levene’s test, we decided
to report data as expressed by mean and standard deviation.
In consideration of the exploratory nature of the study, we
referred to levels of significance of p value\0.05. All tests
were two-tailed.
Results
Demographic and clinical characteristics of CM patients
with MO at baseline are below depicted. The population
consisted of 63 patients (81 % female), aged between 23
and 71 years (mean age = 42.1, SD = 10.2). The pre-
existing primary headache subtype was migraine without
aura.
Most active constituents for migraine acute treatment
were simple analgesics, triptans and low doses of opiates
in combination with non-opiate analgesics. 21 patients
fulfilled ICHD criteria for triptan-overuse headache, 33
those for of NSAID overuse headache. The other nine
patients could not be subclassified as they used at least
both classes of medication. An analysis of variance was
performed on the basis of different symptomatic medi-
cations used for migraine attack. We found no significant
differences in the clinical and psychological studied
domains.
Different preventive medications, single or in combi-
nation, were or had been used in the sample according to
patients’ clinical status (valproic acid, topiramate, beta-
blockers, amitriptyline, flunarizine). At baseline, 28 patients
were off preventive treatment before due to lack of efficacy
while 35 were under single compound or combination pro-
phylaxis. After detox, 31 patients were given prophylaxis to
control possible attacks. An on–off prophylaxis split analysis
was performed, notwithstanding the type and the amount of
different medications. From the series of t tests for inde-
pendent samples, no difference emerged across the clinical,
psychological and affective and measures.
Our sample was characterized by a long duration of
migraine history (mean years with migraine = 23.34,
SD = 13.08, minimum 1 year, maximum 60 years) of
medication overuse (mean years with overuse = 2.76,
SD = 5.96, minimum 3 months, maximum 36 years). The
intensity of headache pain on VAS (mean = 7.71,
SD = 1.61), the frequency of headaches (mean episodes
per month = 22.19, SD = 6.54), and medication intake
(mean number of tablets per month = 32.95, SD = 23.21)
accounted for the high very high rates headache-related
disability (mean MIDAS score was 68.87 with a 49.86 SD)
and severe dependency-like behaviors (mean SDS score
was 8.67 with a 2.19 SD; cut off for medication depen-
dence is 5).
Twenty-four subjects (38.7 %) had a past history of
mood or anxiety disorder; after Axis 1 clinical evaluation
18 patients (29 %) were, respectively, diagnosed with an
anxiety or depressive disorder. No significant differences in
the clinical and psychological studied features were found
between those who had or had had a psychiatric disorder
and those who did not.
Correlational analysis (Table 1) revealed that all the
measured clinical variables (years with migraine, years
with medication overuse, frequency of headache per
month, number of tablets per month, intensity of headache
pain) went through reciprocal influences that contribute as
independent factors in determining the headache-related
disability as measured by MIDAS.
After 1 year of follow-up, 21 out of the 63 patients
who originally underwent the detoxification dropped out
(33 %): 4 fell into the exclusion criteria: 2 for suicide
attempt and 2 for pregnancy, 10 referred to other headache
centers, 4 did not came for follow-up visit; 3 patients
relapsed into MO within a month after detoxification and
were, therefore, excluded from longitudinal analyses. No
significant differences in baseline characteristics were
found between dropouts and those who completed study
follow-up. Data for longitudinal statistical inferences are
indeed available for 42 patients: according to ICHD-II
criteria, 31 of them ceased MO and restored an episodic
migraine pattern while 11 patients, in spite of the tempo-
rary resolution of MO, relapsed into MO within 1 year
after detoxification. Considering the follow-up sample
regardless of relapse (Table 2a), subjects showed signifi-
cant decreases in most clinical and psychological tested
domains (frequency of headaches per month, number of
tablets per month, intensity of headache pain, MIDAS total
score, GSI at SCL-90R questionnaire, scores at Hamilton
Rating Scale for Depression, SDS score). These findings
highlight the benefit of detoxification. A comparative t test
analysis for independent samples between those with
positive and negative outcomes (Table 2b) showed expected
differences in some clinical measurements, such as the
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tablets intake and headaches frequencies. Patients who
relapsed into MO were more anxious (15.55 ± 8.13 vs.
10.19 ± 5.86) with maladaptive dependency-like behaviors
(powerlessness, medications unmanageability, loss of con-
trol over medications despite the adverse consequences over
headache). Mean SDS score in the negative outcome sub-
group was unmodified compared to baseline (9.36 ± 2.06).
A series of bivariate analyses was performed to
identify risk factors for long-term relapse, headache-
related disability and medication intake. Three separate
analyses were conducted as preliminary inspections
propaedeutic for running a subsequent multivariate
regression analysis to detect predictors. However, the
scant sample numerosity would not have allowed any
inference for a putative multivariate regression model. In
addition, no explanatory variables were found for any of
selected outcomes.
Discussion
The identification of relapse predictors is still an unac-
hieved target in chronic migraine with medication overuse.
The results from 1-year and 4-year follow-up studies are
currently inconsistent. Many researchers pointed out the
severity of baseline migraine as source of the main out-
come predictors [12, 20]. However, long-term prospective
studies were not equally encouraging, indicating that few
or none of the baseline characteristics significantly influ-
enced the outcome measures [11]. Anxiety and mood
symptoms have been considered capable of influencing the
long-term outcome. In their 4-year follow-up study, Hagen
and colleagues [21] reported that a low depression score at
baseline was the only factor associated with a favorable
outcome. As Table 2a shows, our sample was affected by
severe chronic migraine and MO characterized by severe
dependency-like behaviors, significant anxiety and depre-
ssion levels.
Pearson analysis showed that the higher is the medica-
tion intake, the longer are the history of MO, the frequency
of migraine episodes and the intensity of headache pain.
Furthermore, the longer is the history of migraine, the
higher are the medication intake and the duration of MO.
Therefore, the headache-related disability directly results
from the frequency and the intensity of migraine episodes.
Most studied variables have reciprocal influences that
blurred the clinical presentation to the degree that it was no
longer possible to determine the single role of each variable
in contributing to the overall impairment and optimize
individual-tailored treatment. The severity of our sample is
confirmed by the symptomatic and prophylactic poly-
therapy the patients were kept on. On–off split analyses
were performed on the basis of different symptomatic and
prophylactic medications for clinical, psychological and
affective measures. The lack of significant differences
might derive from the subcategories’ overlap, given the
great variability of medication protocols in comparison
with the small size of the sample.
We selected the presence of relapse, the headache-
related disability and the number of tablets per month as
the three major indicators of positive outcome after 1 year.
Neither the type of medication overused nor the presence
of a prophylactic therapy predicted any of three selected
outcomes. Again, the complexity of therapeutic protocols
might account for the lack of significance in results.
Beyond the evidence that the follow-up sample showed
significant improvements in most of the clinical and
affective measures regardless of relapse, the improvement
of clinical, affective and dependence symptoms results
partial.
In this study, we tried to delineate the features of a
sample of highly impaired chronic migraineurs with MO.
Table 1 Bivariate statistical analysis with Pearson’s product-
moment correlation among clinical measurements at baseline
Correlations
Years with
medication
overuse
Frequency
of
headaches
per month
Number
of tablets
per
month
Intensity
of
headache
pain on
VAS
Years with migraine
Pearson
correlation
0.329** 0.157 0.283* -0.036
Sig. (2-tailed) 0.008 0.220 0.025 0.780
Years with medication overuse
Pearson
correlation
1.000 0.173 0.456 0.207
Sig. (2-tailed) 0.176 0.000 0.103
Frequency of headaches per month
Pearson
correlation
0.173 1.000 0.375 0.203
Sig. (2-tailed) 0.176 0.002 0.111
Number of tablets per month
Pearson
correlation
0.456** 0.375** 1.000 0.341
Sig. (2-tailed) 0.000 0.002 0.006
Intensity of headache pain on VAS
Pearson
correlation
0.207 0.203 0.341** 1.000
Sig. (2-tailed) 0.103 0.111 0.006
MIDAS total score
Pearson
correlation
0.203 0.311* 0.219 0.370**
Sig. (2-tailed) 0.111 0.013 0.085 0.003
* Correlation is significant at the 0.05 level (2-tailed)
** Correlation is significant at the 0.01 level (2-tailed)
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Specifically, we decided to test some clinical and affective
variables known to predict relapse after a successful
detoxification. We did not find risk factors for any of the
three selected outcomes at 1-year follow-up (the presence
of relapse, the headache-related disability and the number
of tablets per month). We hypothesize that detoxification
brings improvements in most of the clinical and affective
measures, but does not free these severely affected
migraineurs from significant pain intensity, headache-
related disability and dependency-like behaviors, which
place them at risk for new chronicity and recurrent relap-
ses. The partial benefit from detoxification and the severity
bias led us to consider this subgroup of chronic-relapsing
migraneurs as a separate phenotype, whose features might
belong to the substance use disorders spectrum. Recent
findings from neuroimaging and neuropsychological stud-
ies give strength to this hypothesis [6–8, 30]. However, this
study has a number of limitations. First, due to the high
proportion of dropouts (a further indicator of severity
within our sample), we could not determine whether these
patients would have had a worse clinical and affective
profile. Second, the sample size might account for the lack,
the limited reliability and the exploratory nature of these
preliminary findings. Third, the considered variables, as
shown by Pearson analysis, went through a degree of
reciprocal influences that could affect the attempt of
determining the single predicting value.
Further studies are needed to design specific manage-
ment protocols for migraine according to the medication
overuse severity. Since we believe changes in pain locus of
control fundamental for treatment outcomes, we suggest a
multidisciplinary therapeutic program for CM patients with
MO.
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